Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases
Omeros Corporation (OMER)
Last omeros corporation earnings: 3/2 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.omeros.com
Company Research
Source: Business Wire
-- Targeted Complement Activating Therapy™ Represents Next-Generation, Broadly Applicable Antimicrobial Therapeutics – SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the first public presentation of its proprietary Targeted Complement Activating TherapyTM (T-CATTM) platform will occur at the European Congress on Infectious Diseases 2025 in Rome, Italy on Monday, April 14. The plenum presentation, titled Augmenting cytotoxicity of pathogen-specific antibodies which initiate complement activation independent of the classical pathway, will be delivered by Prof. Wilhelm Schwaeble, Ph.D., D.Sc., Director of Research DVM at the University of Cambridge and Director of the Omeros-Cambridge Center for Complement and Inflammation Research.Omeros’ T-CAT platform presents a novel class of pathogen-targeting recombinant antibodies designed for broad applicability against diverse microbial species, including multidrug-resistant organisms (MDROs), without promoti
Show less
Read more
Impact Snapshot
Event Time:
OMER
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OMER alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OMER alerts
High impacting Omeros Corporation news events
Weekly update
A roundup of the hottest topics
OMER
News
- Omeros Corporation (OMER): Novo Nordisk Deal Creating Buzz [Yahoo! Finance]Yahoo! Finance
- Omeros (NASDAQ:OMER) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.MarketBeat
- Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906) [Yahoo! Finance]Yahoo! Finance
- Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)Business Wire
- Omeros: Key Milestone Ahead, Risk-Averse Investors Should Avoid [Seeking Alpha]Seeking Alpha
OMER
Earnings
- 11/13/25 - Beat
OMER
Sec Filings
- 12/1/25 - Form 8-K
- 11/14/25 - Form 424B5
- 11/14/25 - Form S-3ASR
- OMER's page on the SEC website